LYKALABS Top Management

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>LL</div>
LYKALABS -- India Stock  

INR 20.00  0.10  0.50%

LYKA LABORATORIES employes about 4 people. The company is managed by 1 executives with total tenure of roughly 10 years, averaging almost 10.0 years of service per executive having 4.0 employees per reported executive. Analysis of LYKA LABORATORIES management performance can provide insight into the company performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with LYKA LABORATORIES future performance. Additionally, see Stocks Correlation.

Search Insiders

  Piyush Hindia  Executive
Company Secretary

LYKA LABORATORIES Management Team Effectiveness

LYKA LABORATORIES has return on total asset (ROA) of (2.57) % which means that it has lost $2.57 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (408.61) %, meaning that it generated substantial loss on money invested by shareholders. LYKA LABORATORIES management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities.

LYKA LABORATORIES Workforce Comparison

LYKA LABORATORIES is currently regarded as number one stock in number of employees category among related companies. The total workforce of Biotechnology industry is now estimated at about 2,545. LYKA LABORATORIES adds roughly 4.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.


The company has Profit Margin (PM) of (93.85) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (13.32) % which suggests for every $100 dollars of sales it generated a net operating loss of -0.13.

LYKA LABORATORIES Benchmark Summation

The output start index for this execution was zero with a total number of output elements of sixty-one. LYKA LABORATORIES Price Series Summation is a cross summation of LYKA LABORATORIES price series and its benchmark/peer. View also all equity analysis or get more info about price series summation math operators indicator.


Piyush Hindia Company Secretary

About LYKA LABORATORIES Management Performance

The success or failure of an entity such as LYKA LABORATORIES often depends on how effective the management is. LYKA LABORATORIES management team is responsible for propelling the future growth in the right direction and for administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of LYKALABS management before purchasing its stock. It's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the LYKALABS management is utilizing all available resources in the best possible way? Also, how well is the company doing, relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity. Please read more on our stock advisor page.
Lyka Labs Limited engages in manufacturing pharmaceutical formulations and active pharmaceutical ingredients various therapeutic segments in India. Lyka Labs Limited was incorporated in 1976 and is based in Mumbai, India. LYKA LABORATORIES operates under Biotechnology classification in India and is traded on National Stock Exchange of India.

LYKA LABORATORIES Manpower Efficiency

Return on LYKA LABORATORIES Manpower

Revenue Per Employee161.3 M
Net Loss Per Employee151.3 M
Additionally, see Stocks Correlation. Please also try Portfolio Anywhere module to track or share privately all of your investments from the convenience of any device.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page